Right Hip Joint Effusion With Synovitis Is Again Demonstrated

Ther Adv Musculoskelet Dis. 2010 Dec; ii(half dozen): 349–359.

The Role of Synovitis in Osteoarthritis

Philip Thou. Conaghan

^two Department of Musculoskeletal Illness, Leeds Found of Molecular Medicine, University of Leeds, and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, Britain

Abstract

Osteoarthritis (OA) is the most common form of arthritis worldwide yet at that place is yet a lack of effective treatments for this condition. Increasingly, attention has turned to the role of the synovium in OA as it is now recognized, in role from the use of modern imaging techniques, that synovitis is both common and associated with hurting. This offers a target for treatment, for both symptom and potential structure modification. In this review we discuss the evidence for histological and imaging-detected synovitis and the current function of antisynovial therapies in OA.

Keywords: osteoarthritis, synovitis, histology, magnetic resonance imaging, ultrasound

Introduction

Osteoarthritis (OA) is the near prevalent form of arthritis worldwide, a major cause of joint pain and disability and the most common reason for full hip and knee replacement. There are over viii meg people in the United Kingdom living with OA and a 2003 survey of virtually 2000 people with OA constitute that 81% are in constant pain or are limited in their scope to perform everyday tasks. It is estimated that most half of the adult population of the USA will have symptomatic articulatio genus OA past the age of 85, with the highest risk among those that are obese [Irish potato et al. 2008]. OA also has huge economic implications due to an increasing number of joint replacements, increasing hospital charges and an ageing population [Kim, 2008]. In 2004 the USA national bill for hospital charges for hip/knee replacements was US$26 billion and, if the current trend persists, it is estimated that 600,000 hip replacements and ane.iv million genu replacements will be performed in the US in 2015 [Kim, 2008].

Despite this, there is still a real lack of prophylactic and effective treatments for OA, disallowment surgery and acetaminophen, and fzurther treatments are desperately required. Over recent years, attention has turned to the importance of synovitis in OA, although OA is non traditionally considered a classical inflammatory arthropathy, due to the relative lack of neutrophils in the synovial fluid and the lack of systemic manifestations of inflammation. OA symptoms however oft include joint pain, swelling and stiffness, suggestive of at least local inflammation [Pelletier et al. 2001]. It is at present recognized that synovitis is common in OA, both in early and late OA and this offers a potential target for treatment, both for symptom and potential structure modification.

Abnormalities in the osteoarthritis synovium

The gold standard for the diagnosis of synovitis is histology. The normal synovium is composed of 1—4 layers of cells which merge on their deep surface with a zone of loosely arranged fibrocollagenous tissue containing adipocytes, fibro-blasts, mast cells and macrophages. The synovial membrane has an arable blood and nerve supply running throughout the loose fibrocollagenous tissue.

Biopsies from the synovium of OA knees (taken at arthroscopy for genu pain or at joint replacement) take demonstrated several key changes in the synovium, which although more pronounced in advanced OA, are present from the earliest stages of the OA procedure [Loeuille et al. 2005; Smithed al. 1997; Myers et al. 1990]. These synovial abnormalities include:

thickening of the lining layer;
increased vascularity;
inflammatory prison cell infiltration.

Synovial membrane histology in classical inflammatory arthritides such as rheumatoid arthritis (RA) is characterized by a wide heterogeneity. OA synovium besides displays this spectrum of changes, although there is a bottom caste of inflammation than in RA. The OA spectrum ranges from marked hyperplasia of the lining layer, with a dense cellular infiltrate composed largely of lymphocytes and monocytes, through to a synovial membrane which is thickened by fibrotic tissue [Haraoui et al. 1991]. Surface fibrin degradation and fibrosis within the synovium is mutual in OA, especially in the afterward stages [Loeuille et al. 2005].

Straight comparison of the synovium between 12 OA subjects and eighteen RA subjects at time of total human knee replacement has shown more than hyperplasia of the lining jail cell layer and cellular infiltrate in astringent RA (treated with steroids and methotrexate) than in OA. However, in milder RA (subjects treated with nonsteroidal anti-inflammatory drugs [NSAIDs] only) the histological changes are like to those seen in OA [Haraoui et al. 1991].

The synovitis seen in OA knees tends to be lengthened and is by and large not localized to areas of chondral defects, although an clan has been reported between chondral defects and associated synovitis in the medial tibiofemoral compartment of the genu [Ayral et al. 2005; Loeuille et al. 2005]. Interestingly, work by Blom and colleagues demonstrated that in an OA mice model, using an MMP3-knockout model, macrophage activation in the synovium is essential for cartilage damage via the product of matrix metalloproteinases (MMPs), suggesting that inflammation within the synovium may be pivotal for cartilage damage [Blom et al. 2007].

How common is histological synovitis in osteoarthritis?

There is increasing evidence that synovitis is common in OA joints, particularly when the affliction has been present for some time.

Microscopic changes in early osteoarthritis

A written report of 29 people with knee pain and arthroscopic evidence of OA (chondropathy) but with no or minimal radiographic changes of OA demonstrated that over one-half accept synovitis histologically, as defined past proliferation of the lining cells and increased mononuclear prison cell infiltration [Myers et al. 1990]. Work by Benito and colleagues in a smaller group of 25 patients demonstrated that early OA patients (normal XR with arthroscopic chondropathy) have a higher level of macrophage infiltration in the synovium, more than blood vessel proliferation and higher markers of vascular proliferation than late OA patients (at the time of joint replacement) [Benito et al. 2005].

Microscopic changes in late osteoarthritis

A larger study of 104 subjects fulfilling American College of Rheumatology (ACR) criteria for OA nerveless synovial samples at fourth dimension of full knee or hip replacement, and demonstrated all-encompassing synovitis, equally assessed by a semiquantitative score. Severe synovial inflammation was shown in 31%, with merely 7 out of the 104 patients having no testify of synovitis. Synovial inflammation was not confined to patients with extensive radiographic joint harm or end-stage disease. Lymphoid aggregates (commonly suggestive of a classic inflammatory arthritis such as rheumatoid) were noted in the severely inflamed synovial samples [Haywood et al. 2003].

Smith and colleagues studied 36 patients with knee pain and a normal knee joint radiograph and 27 with severe articulatio genus OA needing joint replacement. Considerable variation in the synovial lining thickness of the synovial lining layer was seen, with some overlap between normal knees and early OA, nevertheless the scores for synovial cellularity, vascularity and inflammation were markedly increased in the OA synovium compared with normal knees, and with OA synovium at time of joint replacement showing the highest degree of change. Lymphoid aggregates in the synovium were not seen in normal tissue and but rarely in early on OA, but were present in a tertiary of astringent OA synovial membranes, often resembling the synovial membranes of RA [Smith et al. 1997].

Cells and cytokines in the osteoarthritis synovium

Infiltration of the synovium with activated B cells and T lymphocytes and overexpression of proinflammatory mediators is mutual in both early and tardily OA [Benito et al. 2005]. Infiltration with B cells has been demonstrated in the synovium of half of OA knees in a group of 41 subjects fulfilling ACR criteria for human knee OA, who presented with knee pain and/or joint swelling [Da et al. 2007]. Interestingly, piece of work by Benito and colleagues demonstrated that patients with early OA have a higher level of mononuclear prison cell infiltration in the synovium compared with late OA, and higher expression of inflammatory mediators, including interleukin (IL)-1, tumour necrosis cistron-blastoff (TNF-ten), vascular endothelial growth factor (VEGF) and intercellular adhesion molecules [Benito et al. 2005].

Smith and colleagues detected the production of IL-ten and b and TNF-x in a sample of 63 OA synovial membranes, taken at time of total joint replacement (late OA) and at fourth dimension of arthroscopy for knee joint pain (OA diagnosis based on chondropathy). Levels of IL-1 and TNF were elevated in both early and late OA, however these cytokines increase in production with a statistically pregnant increase in moderate and severe OA (p< 0.05). This increase in cytokines is idea to be due to an increment in lining layer cells of the synovium [Smith et al. 1997].

There is besides evidence for T-cell activation and the production of Th1 cytokines (for instance, interferon-thou) in OA, with T cells and T-jail cell infiltrates seen in the synovial membrane [Sakkas and Platsoucas, 2007]. There is excessive production of cytokines and growth factors by the inflamed synovium and activated chondrocytes and these are thought to play a key function in the pathophys-iology of OA [Goldring, 2001; Pelletier et al. 2001; Smith et al. 1997]. These factors may be initially produced by the synovial membrane and lengthened into the cartilage via the synovial fluid [Pelletier et al. 2001] (Figure i).

An external file that holds a picture, illustration, etc. Object name is 10.1177_1759720X10378373-fig1.jpg

Schematic representation of cardinal pathological events and potential targets for disease modification in osteoarthritis. Mediators that represent potential therapeutic targets have been identified in both synovial tissue and cartilage. Less well identified are targets derived from bone. BMP, bone morphogenic protein; IL, interleukin; MMP, matrix metalloproteinase; NO, nitric oxide; PA, plasminogen activator; PGE₂, prostaglandin E_three; TGF, transforming growth factor; TIMP, tissue inhibitor of metalloproteinase; TNF, tumour necrosis factor. (Adjusted by permission from Macmillan Publishers Ltd: [Nature Clinical Practice Rheumatology] (Abramson et al. 2006), copyright (2006).)

Studies in vitro and in vivo have demonstrated that IL-1 and TNF-x are the predominant pro-inflammatory and catabolic cytokines involved in the initiation and progression of articular cartilage destruction in OA [Goldring, 2001]. These cytokines stimulate chondrocytes to produce chemicals such as MMPs, which degrade matrix proteins and collagen. Chondrocytes then produce further IL-1, which then further stimulates MMP product. In human being OA samples, chondrocytes produce more TNF-ten and TNF-10 convertase enzyme than normal cartilage and limited higher quantities of the p55 TNF-ten receptor, suggesting that OA cartilage may be more susceptible to damage from TNF-x than normal cartilage [Fernandes et al. 2002]. The increased levels of catabolic enzymes, prostaglandins, nitric oxide (NO) and other markers in OA fluids and tissues appear to be related to elevated levels of IL-one and TNF-x [Goldring, 2001]. IL-6 is too upregulated during synovial inflammation and is produced by synovial cells, osteoblasts and chondrocytes and can be detected in synovial fluid samples taken from OA joints [Bonnet and Walsh, 2005].

Angiogenesis in the osteoarthritis synovium

Synovial and osteochondral angiogenesis are also features of OA and markers of angiogenesis in the synovium accept been associated with histological synovitis, suggesting that angiogenesis may contribute to chronic synovitis [Walsh et al. 2007]. More recent work has full-bodied on the potential part of VEGF in the OA synovium. VEGF is a strong stimulator of angiogenesis and macrophages and mast cells, nowadays in affluence in chronically inflamed OA synovium, accept been shown to produce VEGF [Bonnet and Walsh, 2005]. The authors hypothesize that production of VEGF by synovial macrophages is a possible molecular machinery which exacerbates synovial angiogenesis and inflammation in OA [Haywood et al. 2003], although the exact regulation of angiogenesis in an OA joint is non yet completely understood [Ashraf and Walsh, 2008].

In summary, the synovium in OA joints is aberrant, even from the earliest clinical stages, with production of inflammatory cytokines IL-1, IL-half dozen, TNF-x and VEGF, infiltration of mononu-clear cells, thickening of the synovial lining layer and fibrosis.

Modern imaging and osteoarthritis synovitis

Magnetic resonance imaging

MRI has been invaluable in improving our agreement of the role of the synovium in OA. Quantitative MRI markers of synovitis include synovial membrane thickness (ordinarily performed using partition and epitome assay of individual MR slices), synovial fluid volume (besides using segmentation techniques) and the rate of synovial enhancement later intravenous (4) injection of contrast agent such every bit gadolinium-DTPA (diethylenetriamine pentaacetic acid). It has recently been demonstrated that volume acquisition of synovitis may also be combined with the charge per unit of enhancement subsequently IV contrast injection [Loeuille et al. 2009].

Intravenous contrast agents usually incorporate the heavy metal gadolinium, which distributes quickly to vascular tissues. Inflamed (and therefore vascular) synovium is enhanced, with the indicate intensity increasing in proportion to the concentration of gadolinium. It has been demonstrated that synovitis can be accurately quantified without using contrast [Pelletier et al. 2008] and recent concerns over the potential toxicity of gadolinium contrast in those with severe renal impairment means this area warrants farther development. The utilise of Four dissimilarity in MRI allows clear differentiation betwixt synovitis and effusion in large joints, which may be more hard to differentiate on noncontrast imaging, although ultrasound tin differentiate between synovitis and effusion.

The frequency of synovitis in OA knees has been evaluated with MRI. 50 two people with ACR criteria knee OA and a control grouping of 40 normal knees were imaged using noncontrast MRI to appraise synovial thickening. Synovitis (every bit adamant past synovial thickening) was observed in 73% of OA knees compared with 0% of the command group. Synovitis was as well noted to be more likely with increasing K/L grade [Fernandez-Madrid et al. 1994]. This synovial thickening seen on MRI has been confirmed as histological synovitis in a small-scale written report past the same authors, of nine people, using arthroscopic sampling of the areas of MRI detected synovial thickening [Fernandez-Madrid et al. 1995]. A further report confirmed that MR detected synovial changes are confirmed every bit histo-logical synovitis [Loeuille et al. 2005]. This written report assessed 39 people with articulatio genus OA with both not-dissimilarity MRI and arthroscopy to assess the syno-vium macroscopically and accept over 100 biopsy samples for microscopic analysis. The grade of MR synovial thickening correlated well with the degree of macroscopic synovitis seen at arthroscopy (r=0.58) and also with the caste of synovial changes seen microscopically (r = 0.41, p<0.0001). The authors also noted that the distribution of synovitis was diffuse, with no statistical difference seen between those people with marked chondral changes and those with few chondral changes, suggesting again that synovitis is present from the primeval stages of OA and is not related purely to areas of cartilage damage [Loeuille et al. 2005]. Farther piece of work, in a study of 15 subjects, demonstrated that synovial membrane which has a high rate of enhancement on MR imaging after administration of Four contrast was significantly associated with severe microscopic synovial vascular congestion [Loeuille et al. 2009].

Recent imaging studies accept demonstrated an fifty-fifty higher frequency of imaging-detected synovitis in painful OA. A MRI study assessed 87 moderately symptomatic people coming together ACR criteria for knee OA using ane.5-T MRI. Pre- and mail-gadolinium sequences of a single knee were evaluated for semiquantitative synovitis scores at ix intraarticular sites. Distribution of synovitis was all-encompassing with 86% of subjects having synovitis at half dozen or more than sites [Conaghan, 2006].

Having established that MR tin accurately detect synovial thickening and that this is confirmed as histological synovitis, it is of import to understand the relationship between synovitis and symptoms. Three recent studies have demonstrated the human relationship between synovitis in the knee and pain. Hill and colleagues evaluated the association of effusions, popliteal cysts, and synovial thickening with knee symptoms in 381 older persons with both human knee pain and radio-graphic OA, 52 with no articulatio genus pain and radio-graphic OA, and 25 with neither pain nor radiographic changes [Hill et al. 2001]. All underwent MRI of ane genu without the use of IV contrast. The authors noted that without IV contrast, synovitis may exist underestimated and they attempted to distinguish between effusion and synovitis on MR images by oversampling knees with no or small-scale effusions. Synovial thickening was measured as present or absent in 3 intra-articular areas by a trained reader, with a kappa for intra-observer reproducibility of 0.77. There was a significant association (p = 0.006) between synovitis and pain severity in those with knee joint pain and radiographic OA, afterward adjustment for radiographic change, BMI, age, sexual activity and size of effusion. The mean pain score for those subjects with synovial thickening was 47mm on a pain visual analogue scale (VAS), compared with a mean score of 28mm for those without synovial thickening. There was too a pregnant increase (p< 0.001) in the frequency of both effusions (moderate or large) in the painful knees (54%) compared with those without hurting (xv%). Amidst those with pocket-size (course ane) or no knee (course 0) effusion, those with genu pain had a prevalence of synovial thickening of 73.half-dozen% compared with 21.4% of those without articulatio genus pain (p< 0.001, chi-squared) [Hill et al. 2001].

Further work by the same authors assessed the temporal relationship between synovitis and hurting [Hill et al. 2007] in 270 subjects, all of whom had knee pain and radiographic OA, using MRI (without Four contrast) at baseline, xv and xxx months. Synovitis was assessed at three sites using a semiquantitative score 0—iii. Synovitis scoring was validated by comparison of synovitis scores of identical images with and without gadolinium contrast. Synovitis scores were identical in 13/20 cases, and underestimated in the non-contrast cases. Pain was assessed using a VAS for knee hurting in the previous week. There was a significant correlation between change in total synovitis score and change in pain VAS score (p< 0.001, r=0.21) [Loma et al. 2007].

A recent, large MRI study of 454 people (48% women, mean historic period 59) with OA knee, used contrast-enhanced MRI to appraise the presence of synovitis. Synovitis was demonstrated in 80%. Moreover, the presence of extensive synovitis was associated with an adjusted odds ratio for astringent knee pain of nine.2 (3.ii—26.3) [Baker et al. 2010].

Ultrasound

Ultrasound can also be used to detect synovitis with much greater sensitivity than clinical exam. As with MRI, nearly studies have assessed articulatio genus OA, although hip OA and more recently, the role of ultrasound in hand OA have also been examined [Dandy et al. 2008a].

A large EULAR study of 600 people with articulatio genus OA demonstrated synovial hypertrophy or effusion in 46% [D'Agostino et al. 2005]. Synovial hypertrophy was defined as synovial thickening of ≤4mm and effusion recorded as nowadays or absent-minded based on the depth of fluid ≤4mm or ≤ 4mm in the suprapatellar recess. A further large cohort of 106 people aged between 35 and 55 assessed the ultrasound changes in early human knee OA. All subjects had ≤three months knee joint pain but the majority (87%) had either a normal radiograph merely clinical features of OA, or balmy radiographic OA (Yard/50 grade 1) just. A tertiary had synovial thickening (divers as ≤2mm) and 27 had a suprapatellar effusion [Kumm et al. 2009].

A smaller report using ultrasound assessed 41 people with OA knee and demonstrated the presence of synovitis (equally demonstrated by synovial hypertrophy in the superior and lateral recesses) in 59% [Song et al. 2007] using a definition of synovial thickening of 'whatsoever degree of synovial thickening', rather than the stricter definition in the EULAR report. Using contrast-enhanced ultrasound increased this detection rate to 95% (on assessment of the superior recess). Unlike Hill and colleagues' MRI work, this report did not observe an association between VAS hurting and degree of synovitis, although the numbers in the written report were modest [Vocal et al. 2008].

Few studies have examined the OA paw using sensitive imaging techniques; however, the role of ultrasound in painful paw OA has recently been assessed. Xxx vi subjects with painful mitt OA underwent ultrasound imaging, which demonstrated that 46% had greyscale synovitis at baseline [Corking et al. 2008b]. Ultrasound also demonstrated that painful mitt joints were significantly more probable to have synovitis than not-painful paw joints (plt0.001), even so the extent of changes in individual joints did not correlate with the degree of symptoms [Keen et al. 2008b].

Studies which use ultrasound to appraise synovitis in the OA hip generally assess the response to treatment, such equally intra-articular steroid. Studies take suggested that synovitis is detected in 59% of painful OA hips referred for intraarticular steroid [Robinson et al. 2007]. A reproducible, semi-quantitative scoring arrangement for assessing OA changes in the hip joint, including synovitis, has been suggested [Qvistgaard et al. 2006b].

Using imaging to assess therapies

Imaging may be used to evaluate the effectiveness of therapies. A recent study demonstrated a reduction in ultrasound-detected synovial hypertrophy in 75% of recipients of intraarticular steroid for painful hip OA, although information technology should be noted that all subjects were selected on the basis of ultrasound-detected synovitis prior to receiving intra-articular steroid [Micu et al. 2010]. Ultrasound has also been used to assess synovial changes in paw OA subsequently treatment with intramuscular steroid [Bang-up et al. 2010]. MRI may be used pre- and post-treatment to detect changes in synovial volume and enhancement although much of the current prove is in subjects with the classic inflammatory arthritides [Clunie et al. 1999; Ostergaard et al. 1995].

Synovitis and osteoarthritis structural progression

There is certainly a pathophysiological rationale for synovitis being important in cartilage degradation, every bit discussed higher up. There is likewise evidence from imaging studies to suggest that synovitis has an important office in structural degradation of the OA articulation. Ayral and colleagues assessed the importance of synovitis on structural progression in the medial tibial femoral articulation in a large study of 422 subjects with articulatio genus OA. All underwent arthroscopy at baseline and 1 twelvemonth and the primary consequence was the alter in the arthro-scopic chondropathy score. Synovial abnormalities were reported in fifty% and subjects that had an 'inflammatory' appearance to synovium (21%) had an odds ratio (OR) for progression of the chondropathy score of 3.11 (1.07—five.69) [Ayral et al. 2005]. An MR study of 347 knees with minimal baseline cartilage damage has also demonstrated that the presence of synovitis or effusion was associated with an increased chance of fast cartilage loss, OR 3.36 (0.91—12.4) [Roemer et al. 2009]. Higher synovial volumes accept also been shown to correlate with other measures of worsening OA, such as K/L score and joint space narrowing, in a small accomplice of 44 subjects with human knee OA who underwent contrast-enhanced MRI [Krasnokutsky, 2007].

A large, multicentre EULAR prospective study followed over 500 subjects with knee OA for 3 years following a baseline ultrasound examination. The master endpoint of the written report was a knee articulation replacement. The multivariate analysis demonstrated that the presence of a joint effusion at baseline was a pregnant predictor of joint replacement at three years (take chances ratio [HR] 2.63) [Conaghan et al. 2010].

There is besides bear witness that raised systemic inflammatory markers accept a role in future joint damage. C-reactive protein (CRP) levels (indicative of inflammation) are modestly but significantly increased in women with early knee joint OA and higher CRP levels predict those whose illness will progress radiographically over a menstruation of iv years, even later adjustment for weight, age and knee pain or injury [Spector et al. 1997]. Hyaluronic acid (HA) levels have been noted to be elevated twofold in people with OA compared with a control grouping and plasma HA levels correlated with an objective functional capacity score [Goldberg et al. 1991]. Information technology has also been suggested that serum HA levels may predict radiographic progression at 5 years, although poor sensitivity and specificity means this is not currently of clinical use [Sharif et al. 2000].

A recent longitudinal study of over 900 women has demonstrated that plasma IL-6 levels are significantly elevated (even after aligning for age and BMI) in women who take radiographic OA than women without OA. Plasma IL-6 levels have recently been shown to be an independent predictor of radiographic knee OA progression over 15 years [Livshits et al. 2009].

Osteoarthritis analgesic therapies and synovitis

Nonsteroidal anti-inflammatory drugs

Randomized controlled trials have demonstrated that NSAIDs are efficacious at reducing hurting in OA [Zhang et al. 2008]. This efficacy is thought to exist due to an anti-inflammatory, or anti-synovial, upshot. NSAIDs have been shown to reduce both joint pain and the size of effusion on MRI, in a small-scale group of patients with knee joint OA [Brandt et al. 2006] and a large study of 200 people with painful and radiographic articulatio genus OA has demonstrated that ibuprofen reduces the markers of cartilage and synovium metabolism (including CTX-II) during an acute flare of painful knee OA [Gineyts et al. 2004].

Corticosteroids

Corticosteroids, in particular those given intra-articularly, are frequently used in the treatment of OA, and it is presumed that the corticosteroid mechanism of pain reduction is via an event on the synovium [Jones and Doherty, 1996]. Corticosteroids inhibit the production of pro-inflammatory chemicals interleukins 1 and 6 and TNF-x as well every bit decreasing the expression of COX-ii. Steroids also inhibit the generation, proliferation and activation of T cells, which have been shown to infiltrate the synovium in OA joints.

At that place is practiced evidence for the short-term effectiveness (upward to 4 weeks) in recipients of intraarticular IA steroid to the articulatio genus articulation [Arden et al. 2008; Bellamy et al. 2006; Gossec and Dougados, 2004]; those with a genu effusion demonstrating a better response [Arden et al. 2008]. In that location are a number of studies confirming the effectiveness of intra-articular steroid for the painful OA hip [Lambert et al. 2007; Robinson et al. 2007; Qvistgaard et al. 2006a; Margules, 2001].

In that location is a lack of randomized controlled trials assessing the employ of intra-articular steroid in the mitt, peculiarly to the offset carpometacarpal (CMC) joint, for which there is anecdotal evidence [Dieppe, 1991]. The simply randomized controlled trial of intra-articular steroid to the commencement CMC articulation noted no significant difference between steroid and placebo although the study was terminated early due to difficulty in recruitment [Meenagh et al. 2004].

Recently an observational open-label study has confirmed the effectiveness of intramuscular steroid for the treatment of painful hand OA. Thirty 6 patients with confirmed and symptomatic hand OA were given an intramuscular 120mg methyl prednisolone injection. Ultrasound imaging assessed the caste of synovitis before and after steroid. A significant proportion (67%) of patients had an improvement in symptoms at 4 weeks, with 45% having a sustained reduction in pain at 12 weeks [Keen et al. 2010] and there was a tendency for responders to have higher baseline levels of synovitis.

One study has looked at the use of oral steroids in manus OA, using a novel drug (CRx-102) combining oral prednisolone (3mg) and dipyridamole, used to potentiate the action of the steroid [Kvien et al. 2008]. This half-dozen-calendar week randomized, placebo-controlled report of 83 people with painful mitt OA had a primary upshot equally the reduction in hand pain from baseline to half dozen weeks, using the validated AUSCAN questionnaire. This study demonstrated a pregnant reduction in the 48-hr joint pain score at 6 weeks (p = 0.02). This may advise a part for oral steroids in symptomatic relief of hand OA although it should be noted that this study did not evaluate steroid alone versus placebo.

Affliction-modifying antirheumatic drugs in osteoarthritis

There is limited published evidence for the use of any disease-modifying antirheumatic drugs (DMARDs) in OA. Golden and hydroxychloro-quine have been shown to reduce NO production in chondrocyte culture and OA cartilage, suggesting they may accept an anti-inflammatory mechanism in OA [Vuolteenaho et al. 2005]. Although there is very limited published bear witness for the use of hydroxychloroquine in OA [Bryant et al. 1995], there is much anecdotal bear witness that hydroxychloroquine may help sub-groups of patients.

Beast studies in OA have suggested a possible role for methotrexate in reducing cartilage impairment in a rabbit model [Neidel et al. 1998; Mannoni et al. 1993].

In that location are two pocket-sized studies of the utilise of methotrexate in human OA. The showtime, a placebo-controlled report of 89 patients used a small dose of 7.5mg methotrexate for painful knee OA and did not demonstrate whatsoever reduction in hurting at iv months [Holanda, 2007]. Subjects taking methotrexate required less analgesia (paracetamol) than the placebo grouping. The 2nd used 10mg methotrexate weekly for 2 months, for painful paw OA, and demonstrated a significant comeback in hurting at 2 months [Pavelka, 2006].

Anti-TNFs in osteoarthritis

There are few publications regarding the use of anti-TNF agents in OA. A larger, well-conducted written report of 160 patients evaluated the effects of a single injection of intra-articular anakinra (an IL-1 receptor antagonist) to the symptomatic OA knee. No deviation was seen between anakinra and placebo, although there was a trend to an improvement in pain score in the handling group at 4 weeks, compared with placebo [Chevalier et al. 2009].

There is limited evidence for the potential effectiveness of systemic adalimumab and for intraarticular infliximab in small studies of painful manus OA [Fioravanti et al. 2009; Magnano et al. 2007].

Summary

Synovitis is very mutual in the OA articulation and has been associated both with symptoms and with structural progression. Many of the current effective treatments used for OA have an antisynovial result merely further large-calibration clinical trials are needed to ostend the role of antisynovial agents in symptom and structure modification.

Footnotes

This research received no specific grant from whatsoever funding agency in the public, commercial, or not-for-profit sectors.

None declared.

References

Abramson S.B., Attur Thousand., Yazici Y. (2006) Prospects for disease modification in osteoarthritis. Nat Clin Pract Rheumatol two: 304–312 [PubMed] [Google Scholar]
Arden Northward.M., Reading I.C., Hashemite kingdom of jordan Thou.M., Thomas L., Platten H., Hassan A., et al. (2008) A randomised controlled trial of tidal irrigation vs corticosteroid injection in knee osteoarthritis: the KIVIS Study. Osteoarthritis Cartilage 16: 733–739 [PubMed] [Google Scholar]
Ashraf South., Walsh D.A. (2008) Angiogenesis in osteoarthritis. Curr Opin Rheumatol 20: 573–580 [PubMed] [Google Scholar]
Ayral X., Pickering E.H., Woodworth T.Chiliad., Mackillop Northward., Dougados M. (2005) Synovitis: a potential predictive factor of structural progression of medial tibiofemoral human knee osteoarthritis–results of a ane year longitudinal arthroscopic study in 422 patients. Osteoarthritis Cartilage thirteen: 361–367 [PubMed] [Google Scholar]
Baker Thousand., Grainger A., Niu J., Clancy Chiliad., Guermazi A., Crema M., et al. (2010) Relation of synovitis to knee pain using contrast-enhanced MRIs. Ann Rheum Dis, in press. [PMC free article] [PubMed] [Google Scholar]
Bellamy N., Campbell J., Robinson Five., Gee T., Bourne R., Wells G. (2006) Intraarticular corticosteroid for treatment of osteoarthritis of the articulatio genus. Cochrane Database Syst Rev ii: CD005328. [PubMed] [Google Scholar]
Benito M.J., Veale D.J., FitzGerald O., van den Berg W.B., Bresnihan B. (2005) Synovial tissue inflammation in early and belatedly osteoarthritis. Ann Rheum Dis 64: 1263–1267 [PMC free article] [PubMed] [Google Scholar]
Blom A.B., van Lent P.L., Libregts S., Holthuysen A.E., van der Kraan P.K., van Rooijen N., et al. (2007) Crucial role of macrophages in matrix metalloproteinase-mediated cartilage destruction during experimental osteoarthritis: involvement of matrix metalloproteinase iii. Arthritis Rheum 56: 147–157 [PubMed] [Google Scholar]
Bonnet C.S., Walsh D.A. (2005) Osteoarthritis, angiogenesis and inflammation. Rheumatology (Oxford) 44: 7–xvi [PubMed] [Google Scholar]
Brandt K.D., Mazzuca S.A., Buckwalter K.A. (2006) Acetaminophen, like conventional NSAIDs, may reduce synovitis in osteoarthritic knees. Rheumatology (Oxford) 45: 1389–1394 [PubMed] [Google Scholar]
Bryant L.R., des Rosier K.F., Carpenter Yard.T. (1995) Hydroxychloroquine in the treatment of erosive osteoarthritis. J Rheumatol 22: 1527–1531 [PubMed] [Google Scholar]
Chevalier X., Goupille P., Beaulieu A.D., Burch F.10., Bensen W.Grand., Conrozier T., et al. (2009) Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 61: 344–352 [PubMed] [Google Scholar]
Clunie G.P., Wilkinson I.D., Lui D., Hall-Craggs M.A., Paley G.Due north., Edwards J.C., et al. (1999) Changes in articular synovial lining volume measured past magnetic resonance in a randomized, double-blind, controlled trial of intra-articular samarium-153 particulate hydroxyapatite for chronic knee synovitis. Rheumatology (Oxford) 38: 113–117 [PubMed] [Google Scholar]
Conaghan P. (2006) A MRI Study of the Extent of "Gold Standard"-Evaluated Synovitis and its Relationship to Pain in Osteoarthritis of the Articulatio genus. American Higher of Rheumatology: Abstract No 2094. [Google Scholar]
Conaghan P.Yard., D'Agostino M.A., Le Bars Thousand., Businesswoman M., Schmidely Due north., Wakefield R., et al. (2010) Clinical and ultrasonographic predictors of articulation replacement for knee osteoarthritis: results from a large, 3-yr, prospective EULAR study. Ann Rheum Dis 69: 644–647 [PubMed] [Google Scholar]
D'Agostino M.A., Conaghan P., Le Bars M., Businesswoman G., Grassi West., Martin-Mola Eastward., et al. (2005) EULAR report on the employ of ultrasonography in painful knee osteoarthritis. Part 1: prevalence of inflammation in osteoarthritis. Ann Rheum Dis 64: 1703–1709 [PMC free article] [PubMed] [Google Scholar]
Da R.R., Qin Y., Baeten D., Zhang Y. (2007) B cell clonal expansion and somatic hypermutation of Ig variable heavy chain genes in the synovial membrane of patients with osteoarthritis. J Immunol 178: 557–565 [PubMed] [Google Scholar]
Dieppe P.A. (1991) Are intra-articular steroid injections useful for the treatment of the osteoarthritis articulation? Br J Rheumatol xxx: 199. [PubMed] [Google Scholar]
Fernandes J.C, Martel-Pelletier J., Pelletier J.P. (2002) The function of cytokines in osteoarthritis pathophysiology. Biorheology 39: 237–246 [PubMed] [Google Scholar]
Fernandez-Madrid F., Karvonen R.L., Teitge R.A., Miller P.R., Negendank W.G. (1994) MR features of osteoarthritis of the knee. Magn Reson Imaging 12: 703–709 [PubMed] [Google Scholar]
Fernandez-Madrid F., Karvonen R.L., Teitge R.A., Miller P.R., An T., Negendank Westward.M. (1995) Synovial thickening detected by MR imaging in osteoarthritis of the knee confirmed by biopsy as synovitis. Magn Reson Imaging 13: 177–183 [PubMed] [Google Scholar]
Fioravanti A., Fabbroni Thou., Cerase A., Galeazzi M. (2009) Handling of erosive osteoarthritis of the easily by intraarticular infliximab injections: a pilot study. Rheumatol Int 29: 961–965 [PubMed] [Google Scholar]
Gineyts E., Mo J.A., Ko A., Henriksen D.B., Curtis South.P., Gertz B.J., et al. (2004) Effects of ibuprofen on molecular markers of cartilage and synovium turnover in patients with knee osteoarthritis. Ann Rheum Dis 63: 857–861 [PMC complimentary article] [PubMed] [Google Scholar]
Goldberg R.50., Huff J.P., Lenz Yard.E., Glickman P., Katz R., Thonar E.J. (1991) Elevated plasma levels of hyaluronate in patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum 34: 799–807 [PubMed] [Google Scholar]
Goldring M.B. (2001) Anticytokine therapy for osteoarthritis. Expert Opin Biol Ther i: 817–829 [PubMed] [Google Scholar]
Gossec Fifty., Dougados M. (2004) Intra-articular treatments in osteoarthritis: from the symptomatic to the structure modifying. Ann Rheum Dis 63: 478–482 [PMC gratis article] [PubMed] [Google Scholar]
Haraoui B., Pelletier J.P., Cloutier J.Thousand., Faure M.P, Martel-Pelletier J. (1991) Synovial membrane histology and immunopathology in rheumatoid arthritis and osteoarthritis. In vivo effects of antirheumatic drugs. Arthritis Rheum 34: 153–163 [PubMed] [Google Scholar]
Haywood Fifty., McWilliams D.F., Pearson C.I., Gill S.E., Ganesan A., Wilson D., et al. (2003) Inflammation and angiogenesis in osteoarthritis. Arthritis Rheum 48: 2173–2177 [PubMed] [Google Scholar]
Hill C.L., Gale D.G., Chaisson C.E., Skinner Thousand, Kazis L., Gale M.E., et al. (2001) Knee effusions, popliteal cysts, and synovial thickening: clan with human knee pain in osteoarthritis. J Rheumatol 28: 1330–1337 [PubMed] [Google Scholar]
Loma C.Fifty., Hunter D.J., Niu J., Clancy Thou., Guermazi A., Genant H., et al. (2007) Synovitis detected on magnetic resonance imaging and its relation to pain and cartilage loss in genu osteoarthritis. Ann Rheum Dis 66: 1599–1603 [PMC costless commodity] [PubMed] [Google Scholar]
Holanda D. (2007) Baxia dose de methotrexate comparado a placebo em osteoartrite de joelho. Rev Bras Reumatol 47: 334–340 [Google Scholar]
Jones A., Doherty M. (1996) Intra-articular corticosteroids are constructive in osteoarthritis only there are no clinical predictors of response. Ann Rheum Dis 55: 829–832 [PMC free commodity] [PubMed] [Google Scholar]
Keen H.I., Lavie F., Wakefield R.J., D'Agostino M.A., Hammer H.B., Hensor E., et al. (2008a) The development of a preliminary ultrasonographic scoring organisation for features of hand osteoarthritis. Ann Rheum Dis 67: 651–655 [PubMed] [Google Scholar]
Bang-up H.I., Wakefield R.J., Grainger A.J., Hensor E.Chiliad., Emery P., Conaghan P.G. (2008b) An ultrasonographic written report of osteoarthritis of the hand: synovitis and its relationship to structural pathology and symptoms. Arthritis Rheum 59: 1756–1763 [PubMed] [Google Scholar]
Keen H.I., Wakefield R.J., Hensor Eastward.M., Emery P., Conaghan P.G. (2010) Response of symptoms and synovitis to intra-muscular methylprednisolone in osteoarthritis of the paw: an ultrasonographic study. Rheumatology (Oxford) 49: 1093–1100 [PubMed] [Google Scholar]
Kim S. (2008) Changes in surgical loads and economic brunt of hip and genu replacements in the U.s.a.: 1997–2004. Arthritis Rheum 59: 481–488 [PubMed] [Google Scholar]
Krasnokutsky Due south., Samuels J., Attur 1000., Regatte R. (2007) Synovial but not cartilage volumes on MRI predict severity of knee OA. Osteoarthritis Cartilage 15(Suppl C): C28 [Google Scholar]
Kumm J., Tamm A., Lintrop Chiliad. (2009) Association between ultrasonographic findings and bone/cartilage biomarkers in patients with early on-stage genu osteoarthritis. Calcif Tissue Int 85: 514–522 [PubMed] [Google Scholar]
Kvien T.Thousand., Fjeld East., Slatkowsky-Christensen B., Nichols M.j, Zhang Y., Proven A., et al. (2008) Efficacy and safety of a novel synergistic drug candidate, CRx-102, in hand osteoarthritis. Ann Rheum Dis 67: 942–948 [PMC free commodity] [PubMed] [Google Scholar]
Lambert R.G., Hutchings E.J., Grace K.K., Jhangri Thousand.Southward., Conner-Spady B., Maksymowych Due west.P. (2007) Steroid injection for osteoarthritis of the hip: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 56: 2278–2287 [PubMed] [Google Scholar]
Livshits Grand., Zhai Thousand., Hart D.J., Kato B.S., Wang H., Williams F.M., et al. (2009) Interleukin-vi is a meaning predictor of radiographic knee osteoarthritis: The Chingford Study. Arthritis Rheum lx: 2037–2045 [PMC free article] [PubMed] [Google Scholar]
Loeuille D., Chary-Valckenaere I., Champigneulle J., Rat A.C., Toussaint F., Pinzano-Watrin A., et al. (2005) Macroscopic and microscopic features of synovial membrane inflammation in the osteoarthritic knee: correlating magnetic resonance imaging findings with disease severity. Arthritis Rheum 52: 3492–3501 [PubMed] [Google Scholar]
Loeuille D., Rat A.C., Goebel J.C., Champigneulle J., Blum A., Netter P., et al. (2009) Magnetic resonance imaging in osteoarthritis: which method best reflects synovial membrane inflammation? Correlations with clinical, macroscopic and microscopic features. Osteoarthritis Cartilage 17: 1186–1192 [PubMed] [Google Scholar]
Magnano M.D., Chakravarty Due east.F., Broudy C, Chung L., Kelman A., Hillygus J., et al. (2007) A airplane pilot study of tumor necrosis factor inhibition in erosive/inflammatory osteoarthritis of the hands. J Rheumatol 34: 1323–1327 [PubMed] [Google Scholar]
Mannoni A., Altman R.D., Muniz O.Eastward., Serni U., Dean D.D. (1993) The furnishings of methotrexate on normal and osteoarthritic lapine articular cartilage. J Rheumatol 20(5): 849–855 [PubMed] [Google Scholar]
Margules Thousand.R. (2001) Fluoroscopically directed steroid instillation in the handling of hip osteoarthritis: safe and efficacy in 510 cases. Arthritis Rheum 44: 2449–2450; writer reply 2455–2446. [PubMed] [Google Scholar]
Meenagh One thousand.Grand., Patton J., Kynes C., Wright Yard.D. (2004) A randomised controlled trial of intra-articular corticosteroid injection of the carpometacarpal articulation of the thumb in osteoarthritis. Ann Rheum Dis 63: 1260–1263 [PMC free article] [PubMed] [Google Scholar]
Micu M.C., Bogdan G.D., Fodor D. (2010) Steroid injection for hip osteoarthritis: efficacy under ultrasound guidance. Rheumatology (Oxford), in press. [PubMed] [Google Scholar]
Tater Fifty., Schwartz T.A., Helmick C.G., Renner J.B., Tudor G., Koch G., et al. (2008) Lifetime chance of symptomatic knee joint osteoarthritis. Arthritis Rheum 59: 1207–1213 [PMC free article] [PubMed] [Google Scholar]
Myers Due south.Fifty., Brandt 1000.D., Ehlich J.W, Braunstein E.Chiliad., Shelbourne Thou.D., Heck D.A., et al. (1990) Synovial inflammation in patients with early osteoarthritis of the knee. J Rheumatol 17: 1662–1669 [PubMed] [Google Scholar]
Neidel J., Schroers B., Sintermann F. (1998) The effects of loftier-dose methotrexate on the development of cartilage lesions in a lapine model of osteoarthrosis. Arch Orthop Trauma Surg 117: 265–269 [PubMed] [Google Scholar]
Ostergaard Grand., Stoltenberg Grand., Gideon P., Wieslander S., Sonne-Holm S., Kryger P., et al. (1995) Outcome of intraarticular osmic acid on synovial membrane book and inflammation, determined by magnetic resonance imaging. Scand J Rheumatol 24: 5–12 [PubMed] [Google Scholar]
Pavelka K. (2006) Methotrexate in the treatment of erosive OA of the hands. Ann Rheum Dis 65(Suppl ii): 402 [Google Scholar]
Pelletier J.P., Martel-Pelletier J., Abramson S.B. (2001) Osteoarthritis, an inflammatory disease: potential implication for the option of new therapeutic targets. Arthritis Rheum 44: 1237–1247 [PubMed] [Google Scholar]
Pelletier J.P., Raynauld J.P., Abram F., Haraoui B., Choquette D., Martel-Pelletier J. (2008) A new not-invasive method to appraise synovitis severity in relation to symptoms and cartilage volume loss in articulatio genus osteoarthritis patients using MRI. Osteoarthritis Cartilage 16(Suppl 3): S8–S13 [PubMed] [Google Scholar]
Qvistgaard East., Christensen R., Torp-Pedersen S., Bliddal H. (2006a) Intra-articular treatment of hip osteoarthritis: a randomized trial of hyaluronic acid, corticosteroid, and isotonic saline. Osteoarthritis Cartilage 14: 163–170 [PubMed] [Google Scholar]
Qvistgaard E., Torp-Pedersen S., Christensen R., Bliddal H. (2006b) Reproducibility and inter-reader understanding of a scoring system for ultrasound evaluation of hip osteoarthritis. Ann Rheum Dis 65: 1613–1619 [PMC free article] [PubMed] [Google Scholar]
Robinson P., Keenan A.M., Conaghan P.K. (2007) Clinical effectiveness and dose response of image-guided intraarticular corticosteroid injection for hip osteoarthritis. Rheumatology (Oxford) 46: 285–291 [PubMed] [Google Scholar]
Roemer F.W, Zhang Y., Niu J., Lynch J.A., Crema M.D., Marra Chiliad.D., et al. (2009) Tibiofemoral joint osteoarthritis: risk factors for MR-depicted fast cartilage loss over a thirty-month period in the multicenter osteoarthritis study. Radiology 252: 772–780 [PMC free article] [PubMed] [Google Scholar]
Sakkas L.I., Platsoucas CD. (2007) The role of T cells in the pathogenesis of osteoarthritis. Arthritis Rheum 56: 409–424 [PubMed] [Google Scholar]
Sharif M., Shepstone L., Elson C.J., Dieppe P.A., Kirwan J.R. (2000) Increased serum C reactive protein may reflect events that precede radiographic progression in osteoarthritis of the knee joint. Ann Rheum Dis 59: 71. [PMC free article] [PubMed] [Google Scholar]
Smith 1000.D., Triantafillou S., Parker A., Youssef P.P., Coleman M. (1997) Synovial membrane inflammation and cytokine product in patients with early osteoarthritis. J Rheumatol 24: 365–371 [PubMed] [Google Scholar]
Vocal I.H., Althoff C.East., Hermann K.G., Scheel A.K., Knetsch T., Schoenharting M., et al. (2008) Human knee osteoarthritis. Efficacy of a new method of contrast-enhanced musculoskeletal ultrasonography in detection of synovitis in patients with knee osteoarthritis in comparison with magnetic resonance imaging. Ann Rheum Dis 67: 19–25 [PubMed] [Google Scholar]
Spector T.D., Hart D.J., Nandra D., Doyle D.V., Mackillop N., Gallimore J.R., et al. (1997) Low-level increases in serum C-reactive protein are present in early osteoarthritis of the articulatio genus and predict progressive illness. Arthritis Rheum 40: 723–727 [PubMed] [Google Scholar]
Vuolteenaho Yard., Kujala P., Moilanen T., Moilanen Due east. (2005) Aurothiomalate and hydroxychloroquine inhibit nitric oxide production in chondrocytes and in human osteoarthritic cartilage. Scand J Rheumatol 34: 475–479 [PubMed] [Google Scholar]
Walsh D.A., Bonnet C.S., Turner E.L., Wilson D., Situ M., McWilliams D.F. (2007) Angiogenesis in the synovium and at the osteochondral junction in osteoarthritis. Osteoarthritis Cartilage 15: 743–751 [PubMed] [Google Scholar]
Zhang Westward., Moskowitz R.W, Nuki Yard., Abramson S., Altman R.D., Arden N., et al. (2008) OARSI recommendations for the management of hip and knee osteoarthritis, Office II: OARSI evidence-based, proficient consensus guidelines. Osteoarthritis Cartilage 16: 137–162 [PubMed] [Google Scholar]

Articles from Therapeutic Advances in Musculoskeletal Affliction are provided here courtesy of SAGE Publications

sanchezwhentom.blogspot.com

Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3383490/